Human Genome Sciences (HGSI) Misses Q3 EPS by 6c; Cuts Cash, Investments View
Tweet
Share
E-mailGet Alerts HGSI Hot Sheet
Join SI Premium – FREE
Human Genome Sciences, Inc. (NASDAQ: HGSI) reported Q3 loss of ($0.45), $0.06 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $34 million versus the consensus estimate of $37.31 million.
In previous guidance, originally provided in February 2011, HGS expected cash and investments at year-end 2011 to total between $550 million and $650 million. The Company now expects cash and investments at year-end 2011 to total between $440 million and $470 million, net of $79 million principal amount and interest paid upon maturity of the 2011 convertible debt.
In previous guidance, originally provided in February 2011, HGS expected cash and investments at year-end 2011 to total between $550 million and $650 million. The Company now expects cash and investments at year-end 2011 to total between $440 million and $470 million, net of $79 million principal amount and interest paid upon maturity of the 2011 convertible debt.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
